Navigation Links
Over and Under(R) Pericardium Covered Stent is now in use in England and Proves Great Deliverability
Date:6/2/2008

OR AKIVA, Israel, June 2 /PRNewswire-FirstCall/ -- ITGI Medical, Ltd. (TASE: ITGI) announced today the first commercial use of the CE certified Over and Under(R) Pericardium Covered Stent (PCS) in the UK

Over and Under(R) is a stent 100% covered with a heterologous tissue, designed to set a barrier between the coronary blood vessel wall and its lumen. It is intended for situations such as degenerated Saphenous Vein Graft (SVG), aneurysms and perforations.

The first Over and Under(R) PCS commercial implantation and first implantation in the UK was performed at the Royal Bournemouth Hospital whose Percutaneous Coronary Intervention Leader is Dr. Suneel Talwar and the procedure was performed by the Cath Lab director Dr. Rosie Swallow. The medical team granted the procedure as a success due to the special characteristics of the stent and the ease at which the stent was delivered to the lesion.

A pilot study designed to compare the deliverability of a PTFE covered stent vs. Over and Under(R) PCS was presented by Dr. Haim Danenberg, Head of Interventional Cardiology Unit and the company's medical director, at the annual EuroPCR meeting. Study was performed in phantom and porcine coronaries. Over and Under(R) PCS appeared to be significantly superior in deliverability in both model systems.

At its initial step, ITGI launched Over and Under(R) PCS in England, in collaboration with Pyramed, the UK distributor. "We are very pleased with Pyramed's marketing. They have recently purchased the stents and already managed to initiate its use," commented Efri Argaman, CEO of ITGI Medical, "The medical team's satisfaction strengthens our belief that Over and Under(R) PCS ushers in a new era for interventional medicine."

About Over and Under(R)

Over and Under(R) is a unique stent, first in a series of heterologous tissue covered stents, designed to set a barrier between the blood vessel wall and its lumen. Over and Under(R) PCS is indicated for treatment of bypass stenosis, aneurysms and for emergency situations such as perforations.

About ITGI Medical

ITGI medical is engaged with research and development, manufacturing and marketing of heterologous tissue covered stents. Over and Under(R) is the first among series of heterologous covered stents designed to treat coronary lesions and aneurysms.

Contact:

Danna Moran

Director of Marketing

ITGI Medical Ltd.

P: + 972-72-2200335

dannam@itgimedical.com


'/>"/>
SOURCE ITGI Medical LTD
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. ChemoCentryx Demonstrates Recently Discovered Chemokine Receptor CXCR7 is Essential in Tumor Growth
2. National Stem Cell Holding Announces Patent Application for Newly Discovered Cellular Derived Biomaterials for Anti-Aging Applications
3. National Stem Cell Holding in Final Stage Negotiations for Exclusive Licensing of its Recently Discovered Biomaterial for Anti-Aging Applications
4. Safety Profile of TAXUS(R) Liberte(TM) Stent System Highlighted in Worlds Largest Stent Registry
5. Preclinical Research on Coronary Stent with CeloNova BioSciences Polyzene(R)- F Nanocoating Receives Award at CIRSE 2007
6. ARRIVE Registry Analysis Demonstrates Continued Safety and Efficacy of TAXUS(R) Stent in Complex Real-World Patients
7. PCI Guideline Update Stresses Long-Term Anticoagulant Therapy After Treatment With Drug-Eluting Stents
8. Biosensors Receives CE Mark Approval for Its BioMatrix(R) Drug-Eluting Coronary Stent System
9. CV Therapeutics and Medlogics Device Corporation Sign Licensing Agreement for CVTs Innovative Stent Coating Technology
10. Tryton Medical Receives CE Mark Approval for its Side-Branch Stent
11. Boston Scientific Announces Start of Major European Registry Assessing Different Olimus-Eluting Stents
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/22/2017)... (PRWEB) , ... February 22, 2017 , ... ... discovery and development of precision treatments for neurodegenerative diseases, today announced it has ... the ProMIS approach.” This is one of a series of commentaries from ProMIS’s ...
(Date:2/22/2017)... Aethlon Medical, Inc. (Nasdaq: AEMD ... validated the ability of the Aethlon Hemopurifier® to capture ... in immune-suppressed sepsis patients and also contribute to organ ... of the study was to validate the in ... and Herpes Simplex virus 1 (HSV1) by the Hemopurifier®. ...
(Date:2/21/2017)... 2017 Synthetic Biologics, Inc. (NYSE MKT: SYN), ... to protect and restore the health of patients, intends to report ... 2016 on Thursday, March 2, 2017, and to host a conference ... for the call is as follows: U.S. (toll free): ... ...
(Date:2/21/2017)... ... February 21, 2017 , ... Cancer diagnostics workflow solution ... its executive team to lead the development and commercialization of its Cancer Information ... the diagnosis and treatment of cancer. The CIDT addresses the need for curated ...
Breaking Biology Technology:
(Date:1/23/2017)... DENVER , Jan. 23, 2017  The latest ... biometric smartphone prices have dropped dramatically. The quarterly average ... Q1 2013 to $276 in Q4 2016.  There are ... average price of $116, up from just 28 a ... According to Maxine Most , Acuity ...
(Date:1/19/2017)... , Jan. 19, 2017 Sensory ... experience and security for consumer electronics, and ... processing systems and cybersecurity solutions, today announced a ... and financial institutions worldwide to bolster security of ... end-to-end secure user authentication platforms they offer, innerCore ...
(Date:1/13/2017)... 13, 2017 Sandata Technologies, LLC, a ... homecare industry, including Electronic Visit Verification™ (EVV™), announced ... Jugs, as Senior Vice President of Product Management. ... of homecare experience to Sandata, where he will ... to align Sandata,s suite of solutions with the ...
Breaking Biology News(10 mins):